Fig. 2. Cell viability assay in prostate cancer cell lines after EZH2 inhibitors and TRAIL treatment. Cells are exposed for 48 hours. Cell viability is determined using the MTT assay (A, B). A WB assay is performed with specific antibodies against EZH2, DR4, DR5, and β-actin in prostate cancer cell lines (C-E). DR4: death receptor 4, DR5: death receptor 5, EZH2: enhancer of zeste homolog 2, TRAIL: tumor necrosis factor-related apoptosis-inducing ligand, WB: western blot. ^*p<0.05, ^**p<0.01, ^***p<0.001.